

Notice from the Executive Officer: Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program

July 31, 2019

Effective **July 31, 2019**, Erelzi (etanercept) will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients in the treatment of Psoriatic Arthritis.

With the previously listed indications, Erelzi will now be listed on the ODB Formulary/Comparative Drug Index (Formulary) as a Limited Use (LU) benefit for the following:

- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Polyarticular Juvenile Idiopathic Arthritis

Details of the LU criteria for Psoriatic Arthritis will also be posted in the July 2019 Formulary update which can be found on the ministry's website at:

http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx

To further inform healthcare providers and patients, we have also included a Frequently Asked Questions (FAQs) document for reference purposes.

Additional Information:

For pharmacies:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.